Grand Pharmaceutical Group Limited (HKG: 0512)

Grand Pharmaceutical Group Income Statement

Financials in millions HKD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	10,587	10,530	9,562	8,598	6,353	6,591
Revenue Growth (YoY)	2.40%	10.12%	11.22%	35.34%	-3.61%	10.61%
Cost of Revenue	4,340	4,006	3,611	3,351	2,318	2,549
Gross Profit	6,247	6,524	5,951	5,247	4,035	4,041
Selling, General & Admin	3,687	3,802	3,396	3,307	2,545	2,849
Other Operating Expenses	-536.59	-195.17	-170.42	-242.12	-293.48	-217.15
Operating Expenses	3,208	3,665	3,203	3,077	2,252	2,632
Operating Income	3,039	2,860	2,748	2,170	1,783	1,409
Interest Expense	-178.03	-205.15	-137.49	-92.96	-115.42	-146.5
Interest & Investment Income	7.75	7.75	19.81	74.95	18.05	11.15
Earnings From Equity Investments	0.62	-25.01	-43.79	113.86	61.98	114.96
Other Non Operating Income (Expenses)	27.32	-32.34	40.1	-8.35	-	-
EBT Excluding Unusual Items	2,897	2,605	2,627	2,258	1,748	1,389
Merger & Restructuring Charges	-	-	-0.22	-	-	-
Impairment of Goodwill	-39.14	-39.14	-36.44	-	-	-
Gain (Loss) on Sale of Investments	303.36	89.27	-94.62	484.85	271.41	-68.39
Gain (Loss) on Sale of Assets	-	-	-	2.37	8.58	28.38
Asset Writedown	5.45	5.45	21.35	29.58	45.65	6.97
Other Unusual Items	-316.18	-316.18	-	11.42	-	-
Pretax Income	2,850	2,344	2,517	2,786	2,074	1,356
Income Tax Expense	424	448.76	418.64	380.8	292.37	230.49
Earnings From Continuing Operations	2,426	1,895	2,098	2,405	1,781	1,125
Minority Interest in Earnings	-17.79	-15.44	-18.83	-2.47	11.45	25.46
Net Income	2,409	1,880	2,079	2,403	1,793	1,151
Net Income to Common	2,409	1,880	2,079	2,403	1,793	1,151
Net Income Growth	0.43%	-9.59%	-13.45%	34.02%	55.76%	61.50%
Shares Outstanding (Basic)	3,494	3,508	3,542	3,548	3,445	3,278
Shares Outstanding (Diluted)	3,494	3,508	3,542	3,548	3,445	3,371
Shares Change (YoY)	-1.51%	-0.97%	-0.16%	2.98%	2.19%	20.79%
EPS (Basic)	0.69	0.54	0.59	0.68	0.52	0.35
EPS (Diluted)	0.69	0.54	0.59	0.68	0.52	0.34
EPS Growth	1.97%	-8.70%	-13.31%	30.14%	51.15%	29.90%
Free Cash Flow	1,450	1,937	1,216	1,534	1,247	737.91
Free Cash Flow Per Share	0.42	0.55	0.34	0.43	0.36	0.22
Dividend Per Share	0.260	0.260	0.140	0.110	0.110	0.096
Dividend Growth	85.71%	85.71%	27.27%	0%	14.58%	11.63%
Gross Margin	59.00%	61.96%	62.24%	61.03%	63.52%	61.32%
Operating Margin	28.71%	27.16%	28.74%	25.24%	28.07%	21.38%
Profit Margin	22.75%	17.85%	21.75%	27.94%	28.22%	17.46%
Free Cash Flow Margin	13.70%	18.40%	12.72%	17.84%	19.63%	11.20%
EBITDA	3,431	3,212	3,109	2,493	2,055	1,875
EBITDA Margin	32.41%	30.50%	32.52%	28.99%	32.34%	28.45%
D&A For EBITDA	391.68	352.36	361.05	322.53	271.48	465.48
EBIT	3,039	2,860	2,748	2,170	1,783	1,409
EBIT Margin	28.71%	27.16%	28.74%	25.24%	28.07%	21.38%
Effective Tax Rate	14.88%	19.14%	16.63%	13.67%	14.10%	17.00%

Source: S&P Capital IQ. Standard template. Financial Sources.